Archer Aviation reports manufacturing ramp with six aircraft in production
Lisa Egbuonu-Davis, a Director at Phreesia, Inc. (NASDAQ:PHR), sold 465 shares of common stock on July 15, 2025, at a price of $27.64, for a total value of $12852. The sale comes as the healthcare technology company, valued at $1.55 billion, has seen its stock decline nearly 10% over the past week. According to InvestingPro analysis, PHR currently appears undervalued relative to its Fair Value.
Following the transaction, Egbuonu-Davis directly owns 21572 shares of Phreesia, Inc. The sale was executed under a Rule 10b5-1 trading plan adopted on September 24, 2024. While the company isn’t currently profitable, InvestingPro data shows analysts expect profitability this year, with 4 analysts recently revising earnings estimates upward. Discover more insights about PHR and 1,400+ other stocks with InvestingPro’s comprehensive research reports.
In other recent news, Phreesia Inc (NYSE:PHR). reported its first-quarter earnings, showing strong financial performance that exceeded consensus estimates for both revenue and adjusted EBITDA. The company achieved a 16% growth rate in its Subscription and services segment, boosted by approximately $1 million in non-recurring revenue. Despite some challenges in the Network Solutions segment, Phreesia maintained a robust profitability trajectory, with adjusted EBITDA soaring by 408% to $20.8 million, surpassing estimates by about 30%.
Analysts have responded to Phreesia’s financial results with varied perspectives. Piper Sandler maintained an Overweight rating with a $33 target, citing Phreesia’s solid quarterly results and increased guidance for fiscal year 2026. Meanwhile, Canaccord Genuity adjusted its price target to $34 from $35 but kept a Buy rating, acknowledging the company’s continued growth and profitability. DA Davidson also reiterated a Buy rating with a $34 target, highlighting Phreesia’s balance between profit growth and certain challenges.
Additionally, Raymond (NSE:RYMD) James maintained an Outperform rating with a $30 target, emphasizing the company’s strong margins and strategic investments. JPMorgan expressed optimism about Phreesia’s growth prospects, reiterating an overweight rating due to the company’s revenue diversification strategy and recent profitability improvements. These developments reflect ongoing investor interest and confidence in Phreesia’s financial trajectory and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.